Ernexa Therapeutics (ERNAW) Other Non-Current Assets (2010 - 2026)

Ernexa Therapeutics has reported Other Non-Current Assets for 17 years, with the latest figure at $110000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets fell 6.78% year-over-year to $110000.0; the trailing twelve-month figure through Mar 2026 stood at $110000.0 (down 6.78% YoY), and the FY2025 full-year result was $110000.0, down 6.78% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $110000.0, roughly flat from $110000.0 in the prior quarter.
• The five-year high for Other Non-Current Assets was $4.1 million in Q4 2023, with the low at $63000.0 in Q1 2022.
• Historically, Other Non-Current Assets has averaged $1.2 million across 5 years, with a median of $120000.0 in 2024.
• Annual changes were most pronounced in 2023 — Other Non-Current Assets soared 1871.43% — and 2025, when it plunged 97.14%.
• Ernexa Therapeutics' Other Non-Current Assets stood at $1.1 million in 2022, then surged by 261.55% to $4.1 million in 2023, then sank by 97.12% to $118000.0 in 2024, then slipped by 6.78% to $110000.0 in 2025, then changed by 0.0% to $110000.0 in 2026.
• The last three Other Non-Current Assets figures came in at $110000.0 (Q1 2026), $110000.0 (Q4 2025), and $116000.0 (Q3 2025), per Business Quant data.